Glenmede Trust Co. NA Increases Position in AstraZeneca PLC (NASDAQ:AZN)

Glenmede Trust Co. NA boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 191,132 shares of the company’s stock after purchasing an additional 6,808 shares during the quarter. Glenmede Trust Co. NA’s holdings in AstraZeneca were worth $14,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AZN. FMR LLC boosted its holdings in shares of AstraZeneca by 1.1% in the 3rd quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after buying an additional 258,477 shares in the last quarter. Fisher Asset Management LLC lifted its position in AstraZeneca by 5.3% during the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after acquiring an additional 524,175 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in AstraZeneca by 16.7% in the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock valued at $266,565,000 after acquiring an additional 488,644 shares in the last quarter. Clearbridge Investments LLC grew its holdings in AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after purchasing an additional 186,010 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after purchasing an additional 1,605,758 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the topic of several research analyst reports. TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Trading Up 1.3 %

AstraZeneca stock opened at $67.20 on Friday. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The stock has a 50-day moving average price of $72.48 and a 200 day moving average price of $77.50. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $208.36 billion, a price-to-earnings ratio of 32.15, a price-to-earnings-growth ratio of 1.23 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 EPS. Sell-side analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.